| |
FM100 |
FM140 |
P value |
| N=42 |
%, Range |
N=73 |
%, Range |
|
| Median age (year) |
63 |
55-75 |
62 |
55-76 |
0.821 |
| Age>65 years |
15 |
35.7 |
23 |
31.5 |
0.684 |
| Gender; female |
21 |
50 |
39 |
53.4 |
0.847 |
| T-AML |
7 |
16.7 |
8 |
11 |
0.401 |
SWOG Cytogenetic risk [10]
Favorable
Intermediate
High |
4
25
13 |
9.5
59.5
31 |
2
47
24 |
2.7
64.4
32.9 |
0.306 |
ELN risk group [11]
Favorable
Intermediate-I
Intermediate-II
Adverse |
3
10
11
11 |
7.3
24.4
26.8
26.8 |
3
18
12
28 |
4.1
24.7
16.4
38.4 |
0.557 |
| Beyond CR1 |
10 |
23.8 |
25 |
34.2 |
0.174 |
SC source
PB
BM |
17
25 |
40.5
59.5 |
50
23 |
68.5
31.5 |
0.006 |
Donor
MRD
MUD
MMUD and haploidentical donors |
15
15
12 |
35.7
35.7
28.6 |
32
29
12 |
43.8
39.7
16.4 |
0.32 |
| Median CD34+ cell dose (cells/kg) |
3.77x106 |
|
4.00x106 |
|
0.653 |
GVHD prohpylaxis
Tacrolimus+mini-methotrexate
Post-transplant cyclophosphamide |
22
17 |
52.4
40.4 |
65
6 |
89
8.2 |
0.143 |
|
